Mainstreaming genomic testing for mitochondrial disease in Australia
Open Access
- 26 February 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (5) , 658-666
Abstract
Genomic sequencing has transformed the diagnostic approach for mitochondrial disease, yet integration into standard clinical practice is limited by access and funding. We conducted a post-implementation evaluation of genome sequencing (GS) for mitochondrial disease in Australia, which became publicly funded through the Medicare Benefits Scheme (MBS) in November 2023, to allow for broader access to testing. Test request data, including demographics, phenotypic information, and the diagnostic outcomes, were collected from November 2023 to May 2025 from the Victorian Clinical Genetics Services, the current laboratory provider of the MBS-funded service. Test uptake was 26% of predicted, with lower test rates in regional and remote areas. Over the first 19 months, 300 individuals suspected of mitochondrial disease underwent GS with a median turnaround time of 84 days (8 days–218 days). The diagnostic yield was 20%, with 56% of diagnoses in known mitochondrial disease genes. Of these, 70% (24 of 34) were in mitochondrial DNA. Seventeen diagnoses were in individuals who had prior non-diagnostic testing (exome sequencing or gene panel). We demonstrate that publicly-funded GS can deliver meaningful diagnostic outcomes for mitochondrial disease on a national scale. To maximise its impact, attention must now shift towards ensuring equitable access, particularly for regional and remote areas, and embedding sustainable mainstreaming models that support both genetic and non-genetic clinicians.Keywords
Funding Information
- Australian Mitochondrial Disease Foundation (PhD Top Up Scholarship)
- Melbourne Academic Centre for Health - Clinician-Researcher Scholarship
- Royal Children's Hospital Foundation - The Chair in Genomic Medicine
This publication has 43 references indexed in Scilit:
- MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotationsNucleic Acids Research, 2020
- Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretationHuman Mutation, 2020
- Genetics of mitochondrial diseases: Identifying mutations to help diagnosisEBioMedicine, 2020
- The diagnostic utility of genome sequencing in a pediatric cohort with suspected mitochondrial diseaseGenetics in Medicine, 2020
- mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial diseaseEMBO Molecular Medicine, 2018
- Genetic diagnosis of Mendelian disorders via RNA sequencingNature Communications, 2017
- Mitochondrial diseasesNature Reviews Disease Primers, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- The Human Phenotype Ontology: A Tool for Annotating and Analyzing Human Hereditary DiseaseThe American Journal of Human Genetics, 2008
- Clinical spectrum and diagnosis of mitochondrial disordersAmerican Journal of Medical Genetics, 2001